TickerFacts.

NovaBridge Biosciences (NBP): R&D Expense

Annual figures by period end, from SEC filings.

Older than the company's other figures. The latest R&D Expense is for the year ended 2023-12-31, while the company's latest annual report covers the year ended 2025-12-31. Its later filings do not report this line under the concept TickerFacts maps.

810.65M CNY
Year ended 2023-12-31
-6.3%
3-year compound annual growth
+13.7%
5-year compound annual growth
1.21B CNY2010-12-31: 43.60M CNY2017-12-31: 267.07M CNY2018-12-31: 426.03M CNY2019-12-31: 840.41M CNY2020-12-31: 984.69M CNY2021-12-31: 1.21B CNY2022-12-31: 904.90M CNY2023-12-31: 810.65M CNY810.65M CNY
2010-12-31 R&D Expense (CNY) 2023-12-31
Period endedR&D ExpenseChange YoYSource filing
2023-12-31810.65M CNY-10.4%2024-04-30, From 2023-01-01
2022-12-31904.90M CNY-25.4%2024-04-30, From 2022-01-01
2021-12-311.21B CNY+23.2%2024-04-30, From 2021-01-01
2020-12-31984.69M CNY+17.2%2023-05-01, From 2020-01-01
2019-12-31840.41M CNY+97.3%2022-04-29, From 2019-01-01
2018-12-31426.03M CNY+59.5%2021-04-28, From 2018-01-01
2017-12-31267.07M CNYn/a2020-04-29, From 2017-01-01
No annual figure between 2010-12-31 and 2017-12-31.
2010-12-3143.60M CNYn/a2021-04-28, From 2010-01-01